Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 5 records in total 5
    records per page




    Clinical, cerebrospinal fluid and neuroimaging findings in COVID-19 encephalopathy HP encephalopathy MESHD: a case series

    Authors: Raphael Tuma; Bruno Guedes; Rafael Carra; Bruno Iepsen; Julia Rodrigues; Antonio Edvan Camelo Filho; Gabriel Kubota; Maira Ferrari; Adalberto Studart-Neto; Mariana Oku; Sara Terrim; Cesar Lopes; Carlos Eduardo Passos Neto; Matheus Dalben; Julia De Souza; Jose Pedro Baima; Tomas Da Silva; Iago Perissinotti; Maria da Graca Martin; Marcia Goncalves; Ida Fortini; Jerusa Smid; Tarso Adoni; Leandro Lucatto; Ricardo Nitrini; Helio Gomes; Luiz Henrique Castro

    doi:10.1101/2020.08.28.20181883 Date: 2020-09-01 Source: medRxiv

    Objective - To describe the clinical, neurological, neuroimaging and cerebrospinal fluid (CSF) findings associated with encephalopathy HP encephalopathy MESHD in patients admitted to a COVID-19 tertiary reference center. Methods - We retrospectively reviewed records of consecutive patients with COVID-19 evaluated by a consulting neurology team from March 30, 2020 through May 15, 2020. Results - Fifty-five patients with confirmed SARS-CoV-2 were included, 43 of whom showed encephalopathy HP encephalopathy MESHD, and were further divided into mild, moderate and severe encephalopathy HP encephalopathy MESHD groups. Nineteen patients (44%) had undergone mechanical ventilation and received intravenous sedatives. Eleven (26%) patients were on dialysis. Laboratory markers of COVID-19 severity were very common in encephalopathy HP encephalopathy MESHD patients, but did not correlate with the severity of encephalopathy HP encephalopathy MESHD. Thirty-nine patients underwent neuroimaging studies, which showed mostly non-specific changes. One patient showed lesions possibly related to CNS demyelination HP CNS demyelination MESHD. Four had suffered an acute stroke HP stroke MESHD. SARS-CoV-2 was detected by RT-PCR in only one of 21 CSF samples. Two CSF samples showed elevated white blood SERO cell count and all were negative for oligoclonal bands. In our case series the severity of encephalopathy HP encephalopathy MESHD correlated with higher probability of death MESHD during hospitalization (OR = 5.5 for each increment in the degree of encephalopathy HP encephalopathy MESHD, from absent (0) to mild (1), moderate (2) or severe (3), p<0.001). Conclusion - In our consecutive series with 43 encephalopathy HP encephalopathy MESHD cases, neuroimaging and CSF analysis did not support the role of direct viral CNS invasion or CNS inflammation MESHD as the cause of encephalopathy HP encephalopathy MESHD.

    COVID-19 and Guillain-Barre Syndrome - a Case report

    Authors: Amira Sidig; Khabab Abbasher; Mutaz F. Digna; Mohamed Elsayed; Hussien Abbasher; Mohammed Abbasher; Abbasher Hussien

    doi:10.21203/rs.3.rs-48327/v1 Date: 2020-07-24 Source: ResearchSquare

    Coronaviruses are a family of related viruses that cause diseases in mammals and avians. Guillain-Barre syndrome MESHD is a rare disorder in which the body's immune system attacks peripheral nerves.The case:A 65 years old Sudanese male TRANS with no diabetes mellitus HP diabetes mellitus MESHD or hypertension HP hypertension MESHD present to the clinic; On examination, he has upper and lower limb weakness MESHD ( quadriplegia MESHD). The condition was preceded by upper respiratory tract infection HP respiratory tract infection MESHD. Chest X-ray showed features of pneumonia HP pneumonia MESHD Chest CT scan showed multiple bilateral ground-glass opacities and consolidation typical of COVID-19 pneumonia HP pneumonia MESHD. Brain MRI was normal. The COVID-19 nasal swab test was positive. Nerve conduction study showed evidence of polyradiculopathies MESHD with dominant demyelination MESHD supporting the diagnosis of Guillain-Barre syndrome MESHD. The patients died after seven days; because of progressive respiratory failure HP respiratory failure MESHD.

    Acute Demyelinating Encephalomyelitis MESHD ( ADEM MESHD) in COVID-19 infection: A Case Series.

    Authors: Michaela McCuddy; Praful Kelkar; Yu Zhao; David Wicklund

    doi:10.1101/2020.07.15.20126730 Date: 2020-07-17 Source: medRxiv

    Objective: To report three patients infected with COVID-19 with severe respiratory syndrome MESHD requiring intubation, who developed acute demyelinating encephalomyelitis MESHD ( ADEM MESHD). Method: Patient data were obtained from medical records from the North Memorial Health Hospital, Robbinsdale, MN, USA Results: Three patients (two men and one woman, aged TRANS 38 - 63) presented with fatigue HP fatigue MESHD, cough HP cough MESHD and fever HP fever MESHD leading to development of acute respiratory distress syndrome MESHD respiratory distress HP syndrome secondary to COVID-19 infection requiring intubation and ventilatory support. Two patients were unresponsive, one with strong eye deviation to the left and the third patient had severe diffuse weakness MESHD. MRI in all patients showed findings consistent with ADEM MESHD. CSF showed elevated protein in all patients with normal cell count and no evidence of infection MESHD, including negative COVID-19 PCR. All three of the patients received Convalescent plasma SERO therapy for COVID-19. All patients were treated with intravenous corticosteroids and improved, although two responded minimally. Two patients treated with IVIG showed no further improvement. Conclusion: Neurological complications from COVID-19 are being rapidly recognized. Our three cases highlight the occurrence of ADEM MESHD as a postinfectious/immune mediated complication of COVID-19 infection MESHD, which may be responsive to corticosteroid treatment. Early recognition of this complication and treatment is important to avoid long term complications.

    Neurological manifestations associated with COVID-19: a nationwide registry

    Authors: Elodie Meppiel; Nathan Peiffer-Smadja; Alexandra Maury; Imen Bekri; Cecile Delorme; Virginie Desestret; Lucas Gorza; Geoffroy Hautecloque-Raysz; Sophie Landre; Annie Lannuzel; Solene Moulin; Peggy Perrin; Paul Petitgas; Francois Sellal; Adrien Wang; Pierre Tattevin; Thomas de Broucker; - contributors to the NeuroCOVID registry

    doi:10.1101/2020.07.15.20154260 Date: 2020-07-16 Source: medRxiv

    Background: The clinical description of the neurological manifestations in COVID-19 patients is still underway. This study aims to provide an overview of the spectrum, characteristics and outcomes of neurological manifestations associated with SARS-CoV-2 infection MESHD. Methods: We conducted a nationwide, multicentric, retrospective study during the French COVID-19 epidemic in March-April 2020. All COVID-19 patients with de novo neurological manifestations were eligible. Results: We included 222 COVID-19 patients with neurological manifestations from 46 centers throughout the country. Median age TRANS was 65 years (IQR 53-72), and 136 patients (61.3%) were male TRANS. COVID-19 was severe or critical in almost half of the patients (102, 45.2%). The most common neurological diseases MESHD were COVID-19 associated encephalopathy HP encephalopathy MESHD (67/222, 30.2%), acute ischemic cerebrovascular syndrome MESHD (57/222, 25.7%), encephalitis HP encephalitis MESHD (21/222, 9.5%), and Guillain-Barre Syndrome MESHD (15/222, 6.8%). Neurological manifestations appeared after first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19 associated encephalopathy HP encephalopathy MESHD, 7 (5-10) days in encephalitis HP encephalitis MESHD, 12 (7-18) days in acute ischemic cerebrovascular syndrome MESHD and 18 (15-28) days in Guillain-Barre Syndrome MESHD. Brain imaging was performed in 192 patients (86.5%), including 157 MRI (70.7%). Brain MRI of encephalitis HP encephalitis MESHD patients showed heterogeneous acute non vascular lesion in 14/21 patients (66.7%) with associated small ischemic lesion or microhemorrhages MESHD in 4 patients. Among patients with acute ischemic cerebrovascular syndrome MESHD, 13/57 (22.8%) had multi territory ischemic strokes HP ischemic strokes MESHD, with large vessel thrombosis MESHD in 16/57 (28.1%). Cerebrospinal fluid was analyzed in 97 patients (43.7%), with pleocytosis MESHD in 18 patients (18.6%). A SARS-CoV-2 PCR was performed in 75 patients and was positive only in 2 encephalitis HP encephalitis MESHD patients. Among patients with encephalitis HP encephalitis MESHD, ten out of 21 (47.6%) fully recovered, 3 of whom received corticosteroids (CS). Less common neurological manifestations included isolated seizure HP seizure MESHD (8/222, 3.6%), critical illness neuropathy MESHD (8/222, 3.6%), transient alteration of consciousness (5/222, 2.3%), intracranial hemorrhage HP intracranial hemorrhage MESHD (5/222, 2.3%), acute benign lymphocytic meningitis MESHD meningitis HP (3/222, 1.4%), cranial neuropathy MESHD (3/222, 1.4%), single acute demyelinating lesion MESHD (2/222, 0.9%), Tapia syndrome MESHD (2/222, 0.9%), cerebral venous thrombosis HP cerebral venous thrombosis MESHD (1/222, 0.5%), sudden paraparesis MESHD paraparesis HP (1/222, 0.5%), generalized myoclonus HP myoclonus MESHD and cerebellar ataxia MESHD ataxia HP (1/222, 0.5%), bilateral fibular palsy (1/222, 0.5%) and isolated neurological symptoms ( headache HP headache MESHD, anosmia HP anosmia MESHD, dizziness MESHD, sensitive or auditive symptoms MESHD, hiccups MESHD, 15/222, 6.8%). The median (IQR) follow-up of the 222 patients was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). Conclusion: Neurological manifestations associated with COVID-19 mainly included CAE, AICS, encephalitis HP encephalitis MESHD and GBS MESHD. Clinical spectrum and outcomes were broad and heterogeneous, suggesting different underlying pathogenic processes.

    First Case Of SAR TRANS-Coronavirus-2 Sequencing In The Cerebrospinal Fluid Of A Patient With Suspected CNS Demyelinating Disease MESHD

    Authors: Renan Domingues; Maria Cássia Mendes-Correa; Fernando Brunale Vilela de Moura Leite; Ester Cerdeira Sabino; Ingra M Claro; Noely Evangelista Ferreira; Camila Malta Romano; Jaqueline Goes de Jesus; Daniel Wagner de Castro Lima Santos; Diego Zanotti Salarini; Carlos Senne

    doi:10.21203/rs.3.rs-31801/v1 Date: 2020-05-26 Source: ResearchSquare

    The association between coronaviruses and central nervous system (CNS) demyelinating lesions MESHD has been previously shown. However, no case has been described of an association between the novel coronavirus (SARS-COV-2) and CNS demyelinating disease MESHD so far. SARS-COV-2 was previously detected in cerebrospinal fluid (CSF) sample of a patient with encephalitis HP encephalitis MESHD. However, the virus identity was not confirmed by deep sequencing of SARS-COV-2 detected in the CSF. Here, we report a case of a patient with mild respiratory symptoms MESHD and neurological manifestations compatible with Clinically Isolated Syndrome. The viral genome of SARS-COV-2 was detected and sequenced in CSF with 99.74 to 100% similarity between the patient virus and worldwide sequences. This report suggests a possible association of SARS COV-2 infection MESHD with neurological symptoms of demyelinating disease MESHD, even in the absence of relevant upper respiratory tract infection HP respiratory tract infection MESHD signs.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.